Skip to main content
SpringerLink
Log in

Fluid therapy with hydroxyethyl starch for massive blood loss during surgery

  • Original Article
  • Published:
Journal of Anesthesia Aims and scope Submit manuscript

Abstract

Purpose

This clinical trial reports the use of hydroxyethyl starch (HES70/0.55/4) at very high dosages during surgery. HES70/0.55/4 has the lowest molecular weight among all HES products, and thus may have the least side effects. This observational retrospective study clarified the effects of high-dose HES70/0.55/4 on coagulation and renal function up to 1 month after massive bleeding during surgery.

Methods

Of 20875 patients on our surgical database, 31 patients were identified who had lost more than 5000 ml of blood during surgery and had survived for more than 1 month. The fluid balance, and pre- and postoperative laboratory data were analyzed. Patients were assessed using acute kidney injury (AKI) criteria. AKI and non-AKI groups were compared regarding volume of HES70/0.55/4 infused and serum creatinine (Cr) levels before surgery and until 1 month after surgery.

Results

The mean volumes of blood loss, total transfusions, HES70/0.55/4, and urine output during surgery were 8051 ml; 5765 ml; 3085 ml (54 ml/kg); and 1338 ml (2.7 ml/kg/h), respectively. Cr increased, and activated partial thromboplastin time, prothrombin time and international normalized ratio were prolonged postoperatively (0.77–0.9 mg/dl, 34–52 s, and 1.1–1.7, respectively). Of the 31 patients, 13 developed AKI, and 10 of the 13 had recovered at 1 month. Renal impairment due to HES70/0.55/4 was not evident, as shown by the finding that the HES70/0.55/4 amount infused in the AKI patients (53 ml/kg) did not differ from that in the nonAKI patients (55 ml/kg), and there was no relationship between the amount of HES infused and Cr changes.

Conclusion

High-dose HES70/0.55/4 could be safely used in massive bleeding during surgery. HES70/0.55/4 may affect coagulation, but renal impairment was not evident 1 month after surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Adcock WL, MacGregor A, Davies JR, Hattarki M, Anderson DA, Goss NH. Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albumin. Biotechnol Appl Biochem. 1998;28:85–94.

    CAS  PubMed  Google Scholar 

  2. Blümel J, Schmidt I, Willkommen H, Löwer J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion. 2002;42:1011–8.

    Article  PubMed  Google Scholar 

  3. Thyer J, Unal A, Thomas P, Eaton B, Bhashyam R, Ortenburg J, Uren E, Middleton D, Selleck P, Maher D. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins. Vox Sang. 2006;91:292–300.

    Google Scholar 

  4. Roberts I. (Cochrane Injuries Group Albumin Reviewers) Human albumin administration in critically ill patients: systematic review of randomized controlled trials. Br Med J. 1998;317:235–9.

    Google Scholar 

  5. The SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–56.

    Article  Google Scholar 

  6. Johnson ML, Gordon HS, Petersen NJ, Wray NP, Shroyer AL, Grover FL, Geraci JM. Effect of definition of mortality on hospital profiles. Med Care. 2002;40:7–16.

    Google Scholar 

  7. Molitoris BA, Levin A, Warnock DG, Joannidis M, Mehta RL, Kellum JA, Ronco C, Shah SV. Improving outcomes of acute kidney injury: report of an Initiative. Nat Clin Pract Nephrol. 2007;3:439–42.

    Google Scholar 

  8. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:31.

    Google Scholar 

  9. Gan T, Bennett GE, Phillips BB, Wakeling H, Moskowitz DM, Olufolabi Y, Konstadt SN, Bradford C, Glass PS, Machin SJ, Mythen MG. Hextend®, a physiologically balanced plasma expander for large volume use in major surgery: a randomized Phase III clinical trial. Anesth Analg. 1999;88:992–8.

    Google Scholar 

  10. Gallandat HRCG, Siemons AW, Bauss D, Rooyen-Butijn WT, Haagenaars JAM, Oeveren W, Bepperling F. A novel hydroxyethyl starch (Voluven®) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth. 2000;47:1207–15.

    Google Scholar 

  11. Westphal M, Jame MFM, Kozek-Langenecker S, Stocker R, Guidet B, Aken HV. Hydoroxyethyl starches. Anesthesiology. 2009;111:187–202.

    Article  CAS  PubMed  Google Scholar 

  12. Yamazaki H. Effects of low-molecular weight HES on kidney—comparison with low-molecular weight dextran (in Japanese with English abstract). Jpn J Anesthesiol. 1975;24:26–43.

    Google Scholar 

  13. Mishler JM. Synthetic plasma volume expanders—their pharmacology, safety and clinical efficacy. Clin Haematol. 1984;13:75–92.

    CAS  PubMed  Google Scholar 

  14. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125–39.

    Google Scholar 

  15. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethyl starch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet. 2001;357:911–6.

    Google Scholar 

  16. Boldt J, Brosch C, Rohm K, Lehmann A, Mengistu A, Suttner S. Is albumin administration in hypoalbuminemic elderly cardiac surgery patients of benefit with regard to inflammation, endothelial activation, and long-term kidney function? Anesth Analg. 2008;107:1496–503.

    Article  CAS  PubMed  Google Scholar 

  17. Treib J, Haass A, Pindur G. Coagulation disorder caused by hydroxyethyl starch. Thromb Haemost. 1997;78:974–83.

    CAS  PubMed  Google Scholar 

  18. Yamakage M, Sato J, Namiki A. Further potential of hydroxyethyl starch-based plasma substitute (in Japanese with English abstract). J Clin Anesth (Japan). 2005;29:61–73.

    Google Scholar 

  19. Yuasa H, Koga Y. Effects of hydroxyethyl starch on hemostasis system (in Japanese with English abstract). J Clin Anesth (Japan). 1998;22:204–8.

    Google Scholar 

  20. Dalrymple-Hay M, Aitchison R, Collins P, Sekhar M, Colvin B. Hydroxyethylstarch induced acquired von Willebrand’s disease. Cin Lab Haematol. 1992;14:209–11.

    Article  CAS  Google Scholar 

Download references

Conflict of interest

HES70 is a product of Fresenius Kabi Inc. As we found that the second author, Dr. Miyao, had been the medical consultant of this company, we changed the COI form to a new version.

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan

    Toshinari Suzuki, Hideki Miyao, Katsuo Terui & Kaoru Koyama

  2. Information Technology Center, Saitama Medical University, 38 Morohongo, Moroyama, Saitama, 350-0495, Japan

    Michio Shiibashi

Authors
  1. Toshinari Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideki Miyao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katsuo Terui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kaoru Koyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michio Shiibashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshinari Suzuki.

About this article

Cite this article

Suzuki, T., Miyao, H., Terui, K. et al. Fluid therapy with hydroxyethyl starch for massive blood loss during surgery. J Anesth 24, 418–425 (2010). https://doi.org/10.1007/s00540-010-0914-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00540-010-0914-5

Keywords

Search

Navigation